DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Effect of Genetic Variation in the Transporter, OAT3, on the Renal Secretion of Cefotaxime

Information source: University of California, San Francisco
Information obtained from ClinicalTrials.gov on October 19, 2009
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Healthy Volunteer

Intervention: Cefotaxime (Drug)

Phase: N/A

Status: Recruiting

Sponsored by: University of California, San Francisco

Official(s) and/or principal investigator(s):
Kathleen Giacomini, PhD, Principal Investigator, Affiliation: University of California, San Francisco

Overall contact:
Chaline Brown, PharmD, Phone: 415-476-6756, Email: brownc@pharmacy.ucsf.edu

Summary

In the proposed study, we plan to use a genotype to phenotype strategy to study the role of the organic anion transporter, OAT3, in drug response. More specifically we will examine the contribution of OAT3 to the renal clearance of anionic drugs such as cefotaxime by studying individuals with a non-functional (or poorly-functional) variant of OAT3.

Clinical Details

Study design: Diagnostic, Non-Randomized, Open Label, Uncontrolled, Parallel Assignment, Pharmacokinetics Study

Eligibility

Minimum age: 18 Years. Maximum age: 45 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

1. Previous participation in the "SOPHIE" study;

2. Posess a specific genotype for OAT3

Exclusion Criteria:

1. Under 18 years old or over 45 years old;

2. Pregnant (pregnancy status in female subjects will be determined by a urine pregnancy test before study drug administration);

3. They report a prior history of any allergic reaction to cephalosporin antibiotic, or severe hypersensitivity to penicillin;

4. Has a prior history of renal or hepatic dysfunction (renal and hepatic function will also be determined for each subject with prescreening blood tests);

5. Taking a medication that could confound study results (such as known substrates or inhibitors of OATs);

6. They do not consent to participate in the study.

Locations and Contacts

Chaline Brown, PharmD, Phone: 415-476-6756, Email: brownc@pharmacy.ucsf.edu

San Francisco General Hospital, San Francisco, California 94143, United States; Recruiting
Chaline Brown, PharmD, Phone: 415-476-6756, Email: brownc@pharmacy.ucsf.edu
Additional Information


Last updated: September 13, 2005

Page last updated: October 19, 2009

-- advertisement -- The American Red Cross
We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2009